I Rudberg

Summary

Affiliation: Diakonhjemmet Hospital
Country: Norway

Publications

  1. ncbi [CYP genotyping in psychopharmacological treatment]
    Ida Rudberg
    Psykofarmakologisk avdeling, Diakonhjemmet sykehus, 0319 Oslo
    Tidsskr Nor Laegeforen 125:2953-5. 2005
  2. ncbi Heterozygous mutation in CYP2C19 significantly increases the concentration/dose ratio of racemic citalopram and escitalopram (S-citalopram)
    Ida Rudberg
    Department of Psychopharmacology, Diakonhjemmet Hospital, Oslo, Norway
    Ther Drug Monit 28:102-5. 2006
  3. ncbi Impact of the ultrarapid CYP2C19*17 allele on serum concentration of escitalopram in psychiatric patients
    I Rudberg
    Department of Psychopharmacology, Diakonhjemmet Hospital, Oslo, Norway
    Clin Pharmacol Ther 83:322-7. 2008
  4. ncbi Serum concentrations of sertraline and N-desmethyl sertraline in relation to CYP2C19 genotype in psychiatric patients
    I Rudberg
    Department of Psychopharmacology, Diakonhjemmet Hospital, P O Box 85 Vinderen, N 0319, Oslo, Norway
    Eur J Clin Pharmacol 64:1181-8. 2008
  5. ncbi Identification of a novel CYP2C19-mediated metabolic pathway of S-citalopram in vitro
    I Rudberg
    Department of Psychopharmacology, Diakonhjemmet Hospital, N 0319 Oslo, Norway
    Drug Metab Dispos 37:2340-8. 2009
  6. ncbi The complexity of active metabolites in therapeutic drug monitoring of psychotropic drugs
    M Hendset
    Department of Psychopharmacology, Diakonhjemmet Hospital, PO Box 85 Vinderen, 0319 Oslo, Norway
    Pharmacopsychiatry 39:121-7. 2006

Detail Information

Publications6

  1. ncbi [CYP genotyping in psychopharmacological treatment]
    Ida Rudberg
    Psykofarmakologisk avdeling, Diakonhjemmet sykehus, 0319 Oslo
    Tidsskr Nor Laegeforen 125:2953-5. 2005
  2. ncbi Heterozygous mutation in CYP2C19 significantly increases the concentration/dose ratio of racemic citalopram and escitalopram (S-citalopram)
    Ida Rudberg
    Department of Psychopharmacology, Diakonhjemmet Hospital, Oslo, Norway
    Ther Drug Monit 28:102-5. 2006
    ..Higher absolute serum concentrations indicate that this is not compensated for by dose reductions in clinical practice...
  3. ncbi Impact of the ultrarapid CYP2C19*17 allele on serum concentration of escitalopram in psychiatric patients
    I Rudberg
    Department of Psychopharmacology, Diakonhjemmet Hospital, Oslo, Norway
    Clin Pharmacol Ther 83:322-7. 2008
    ..001). In conclusion, a homozygous CYP2C19*17 genotype is associated with lower serum concentration of escitalopram, which might imply increased risk of therapeutic failure...
  4. ncbi Serum concentrations of sertraline and N-desmethyl sertraline in relation to CYP2C19 genotype in psychiatric patients
    I Rudberg
    Department of Psychopharmacology, Diakonhjemmet Hospital, P O Box 85 Vinderen, N 0319, Oslo, Norway
    Eur J Clin Pharmacol 64:1181-8. 2008
    ..To investigate the impact of CYP2C19 genotype on serum concentrations of sertraline and N-desmethyl sertraline in psychiatric patients...
  5. ncbi Identification of a novel CYP2C19-mediated metabolic pathway of S-citalopram in vitro
    I Rudberg
    Department of Psychopharmacology, Diakonhjemmet Hospital, N 0319 Oslo, Norway
    Drug Metab Dispos 37:2340-8. 2009
    ..Identification of SCIT PROP as a metabolic pathway catalyzed by CYP2C19 might explain why impaired CYP2C19 activity has a substantially larger effect on SCIT exposure than estimated from in vitro data based solely on formation of SDCIT...
  6. ncbi The complexity of active metabolites in therapeutic drug monitoring of psychotropic drugs
    M Hendset
    Department of Psychopharmacology, Diakonhjemmet Hospital, PO Box 85 Vinderen, 0319 Oslo, Norway
    Pharmacopsychiatry 39:121-7. 2006
    ..In addition, perspectives on the possibility of using distribution- and activity-weighted plasma concentrations are provided...